According to the latest report by IMARC Group, titled "Pet Diabetes Care Market Report by Solution (Treatment, Glucose Monitoring Devices), Animal Type (Dogs, Cats), Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies, Online Stores), and Region 2025-2033," the global pet diabetes care market size reached USD 2.2 Billion in 2024. Pet diabetes is a common and prominent metabolic disease that affects dogs, cats, and livestock. It requires continuous monitoring of blood sugar levels in animals caused by insulin production. It is treated by taking care of pets and including a healthy diet, exercise, insulin therapy, monitoring, and regular veterinary checkups in their daily routine. Pet diabetes care also involves oral medications that stabilize blood sugar levels, help regulate the glucose levels in the bloodstream, and control the delivery of glucose to the tissues of the body. It aids in maintaining the condition, minimizing unpleasant symptoms of high and low blood sugar levels, and lowering the risks of severe complications, such as dementia, vision loss, urinary tract infections (UTI), skin allergies, and kidney issues.
Global Pet Diabetes Care Market Trends:
The increasing number of pets suffering from diabetes represents one of the key factors driving the demand for pet diabetes care around the world. Moreover, rising concerns among pet parents about the health of their pets are contributing to the market growth. In addition, the advent of smart wearable devices for pets that are integrated with advanced technologies, such as artificial intelligence (AI), machine learning (ML), and the Internet of Things (IoT) to monitor vital signs, is favoring the growth of the market. These devices also alert owners to any changes in these vital signs that may indicate a health issue. Furthermore, the growing number of veterinary diagnostic centers and significant improvements in the veterinary healthcare infrastructure is creating a positive outlook for the market. Apart from this, the increasing adoption of insulin treatment for diabetic dogs and cats that minimizes blood glucose levels by increasing peripheral consumption of glucose and suppressing the production of hepatic glucose is strengthening the growth of the market. On account of the aforementioned factors, the market is anticipated to reach a value of USD 3.9 Billion by 2033, exhibiting a CAGR of 6.43% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Solution, Animal Type, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | ACON Laboratories Inc., Allison Medical Inc., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, i-SENS Inc., Merck & Co. Inc., Trividia Health Inc. (Sinocare), UltiMed Inc. and Zoetis Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800